New hope for rare blood disorder: drug trial targets autoimmune attack
Disease control
Ongoing
This study tests an experimental drug called HMPL-523 for people with warm antibody autoimmune hemolytic anemia (wAIHA), a condition where the immune system mistakenly destroys red blood cells, causing fatigue and other symptoms. The trial involves 110 adults aged 18 to 75 and ai…
Phase: PHASE2, PHASE3 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated May 17, 2026 10:07 UTC